Nature's Sunshine Q1 Results: Strong Execution, But Valuation Stretched Further

What happened

Nature's Sunshine Products reported a "very strong" Q1 2026 with sales up 9% and adjusted EBITDA up 33%, driven by digital channel gains and consultant expansion. The company continues to benefit from cost savings and gross margin improvement, with Asia and North America digital showing particular strength. However, the stock has already risen ~47% over the past year and now trades at roughly 25.7x trailing EPS, well above our DCF-based intrinsic value estimate of $10.52 per share. The operational momentum is real, but the margin of safety has narrowed further, and the underlying MLM regulatory and competitive risks remain. For value-oriented investors, the improving fundamentals do not outweigh the stretched valuation.

Implication

The Q1 results validate management's execution and the digital transformation strategy, with sales and EBITDA accelerating. However, the stock's 47% run-up and valuation at ~25.7x P/E leave little room for error. With thin net margins (~3%), heavy international exposure, and regulatory overhang on the MLM model, the risk/reward is unfavorable at current levels. Investors should monitor for sustained margin expansion and FCF consistency before becoming constructive. A material pullback toward intrinsic value (~$10.50) would offer a better entry point.

Thesis delta

The strong Q1 beat reinforces the operational story but does not change our assessment that the stock is overvalued relative to fundamentals. The improved guidance and digital success are positive, but they are already priced in, and the premium to DCF has widened. The thesis shifts from 'potential sell on stretched valuation' to 'sell on even more stretched valuation' given the market's enthusiastic reaction.